Roundtable Discussion: Debating the Merits of Personalised & Off-The Shelf Therapies to Understand Which Is Better or If Combining the Two Offers the Ultimate Advantage
- Comparing personalised neoantigen therapies versus off-the-shelf approaches in terms of efficacy, tumour specificity, and durability of immune response
- Discussing practical considerations such as cost, scalability, manufacturing timelines, and patient accessibility for each therapy type
- Exploring the potential benefits and challenges of hybrid strategies that combine personalised and off-the-shelf approaches to maximise clinical outcomes